Amarin (AMRN -5.9%) took a big hit today after noting in a filing yesterday that it doesn't expect a decision from the FDA this month on the exclusivity of its heart pill Vascepa. This marks the second straight month a decision on Vascepa has failed to make the FDA's monthly "Orange Book" update. The ruling is a highly anticipated one that could award the company sole marketing rights to the drug.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Feb 25, 2015)
at Zacks.com (Feb 23, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs